FRANKFURT – German drugmaker Merck KGaA drug stopped all remaining clinical studies of the experimental lung cancer vaccine tecemotide, formerly known as Stimuvax, after renewed attempts to show its effectiveness failed. [eap_ad_1] The drug – licensed from U.S. biotech firm Oncothyreon – was being be tested on patients with Stage III non-small cell lung cancer (NSCLC), but disappointing results of a trial in Japan prompted the company to stop all other studies involving tecemotide, it said on Friday.
Merck a year go re-started tests on the treatment, which had failed a previous late-stage clinical trial. (Reuters)
[eap_ad_4]